The Claim
In adults with type 2 diabetes and obesity, administration of bimagrumab for 48 weeks results in a 9.0 cm greater reduction in waist circumference compared to placebo, indicating a preferential reduction in abdominal visceral fat.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and obesity, a drug called bimagrumab reduces waist size by 9.0 centimeters more than a placebo after 48 weeks, and this reduction is specifically due to loss of visceral fat in the abdomen.
See the scientific wording
In adults with type 2 diabetes and obesity, bimagrumab reduces waist circumference by 9.0 cm more than placebo over 48 weeks, indicating preferential loss of abdominal visceral fat, a key driver of metabolic disease.
A drug blocks a signal that normally limits muscle growth, causing muscles to get bigger. Bigger muscles burn more energy, and the body starts breaking down fat stored around the organs in the belly. This fat loss is especially strong in the abdomen, making the waist smaller.
What the research says
1 studyStudy: Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
The study found that people with type 2 diabetes and obesity who took bimagrumab lost 9 cm off their waistline — way more than those who took a placebo — which means it likely targeted the dangerous belly fat that raises diabetes and heart disease risk.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.